Stephen V Liu, MD

Chief of Hematology & Oncology @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, Thoracic Oncologist #TexasLung27 #DCLung27 #HereWeGo

[Stephen V Liu, MD @StephenVLiu]

Save the Date! April 8-10, 2027 at Austin City Limits. The 2027 Texas Lung Cancer Conference. My co-chair, Dr. Tina Cascone, and I have some exciting things planned for our 5th meeting! You won't want to miss #TexasLung27!

https://t.co/SkHAEIpiYv

[Chul Kim @chulkimMD]

Arrived in São Paulo after a red-eye flight!

Looking forward to an engaging and productive ITMIG–LALCA meeting, filled with great discussions, new insights, and opportunities for collaboration.

@Itmig_society @IASLC

[Jarushka Naidoo @DrJNaidoo]

Ph II MDT-Bridge @NatureMedicine in stage II/III NSCLC 'bridging' AEGEAN/PACIFIC:

- 142pts, 92 resectable
- 50 borderline resectable→76% resectable post C2, 62% surgery, 24% CRT

Entering the era of 'conversion trials'
@Oncoalert @MartinReck2 #LCSM
https://t.co/bjrvDCgrQT

[Stephen V Liu, MD @StephenVLiu]

Example of why having multiple agents is helpful. Series @JCOPO_ASCO of 12 pts with EGFR mutant NSCLC who switched to lazertinib due to osimertinib toxicity (pulmonary, cardiac, heme). Both 3G TKIs with similar efficacy but different toxicity profiles.

https://t.co/z8fOseVcAA

[Stephen V Liu, MD @StephenVLiu]

First #ESMO26 highlights episode of the @IASLC podcast Lung Cancer Considered features Drs. @sands_jacob @DrJNaidoo and @FSkoulidis touching on DeLLphi-305, Krascendo 1, and MOIO among others. Very impactful @myESMO meeting for lung cancer!

https://t.co/3jqktZwWDj

[Stephen V Liu, MD @StephenVLiu]

Phase II results for soxataltinib, CNS penetrant selective RET inhibitor, in NSCLC @JTOonline. As 1L therapy, RR 89.3%, TTR 0.9m, PFS 19.3m, intracranial RR 100% (n=4) and TRAEs included AST elevation (71%, G3+ 9%) and notably, diarrhea (79%, G3+ 18%).

https://t.co/sFoCbhGxpS

[ESTS @thoracic]

🫁 November is Lung Cancer Awareness Month.

Finding lung cancer early can make surgery possible - with the aim of a cure.

Don't wait. Get Checked! ✅

In partnership with @LungCancerEu 👇 https://t.co/W4RNgwOo0m

#LungCancerAwareness #GetChecked #ThoracicSurgery

[Stephen V Liu, MD @StephenVLiu]

Inaugural Lung Cancer Treatment Controversies in Porto - candid pros & cons circling big decision points & future directions. So appreciative of organization from Drs. Antonio Araujo and Ana Rodrigues and my fellow co-chairs @delvysra @LuisPaz_Ares & all the amazing faculty!

[Stephen V Liu, MD @StephenVLiu]

Great discussions on maintenance therapies from Drs. Andrea Ardizzoni and Jon Zugazagoitia - great discussion on new options for SCLC here in Porto.

[Stephen V Liu, MD @StephenVLiu]

Lively debate between Drs. @fblackhall and @LuisPaz_Ares on where tarlatamab should be delivered - specialty centers or all centers. Rapidly evolving standards demand changes in infrastructure to ensure access!

[Stephen V Liu, MD @StephenVLiu]

A real pleasure debating Dr. @BenjaminBesseMD in Porto on the ideal placement of BiTEs like tarlatamab - first line vs maintenance. Great points all around - no question that the future is built on this new class of agents.

[Stephen V Liu, MD @StephenVLiu]

Wonderful discussion on biomarkers in SCLC from Dr. @AlvaroQuintanal - application of transcriptional subtype limited by plasticity and heterogeneity. Discusses biologic distinction of SCLC in pts with no history of smoking. And how plasticity will impact BiTEs.

[Stephen V Liu, MD @StephenVLiu]

Very balanced and thoughtful discussion on neoadjuvant therapy and surgery for borderline resectable NSCLC from Dr. @pompili_cecilia - patient selection and multidisciplinary discussion remains critical. Important to note resectability and operability carefully.

[Stephen V Liu, MD @StephenVLiu]

Dr. @ChristianRolfo delves into MRD to guide adjuvant therapy in NSCLC. The big debate: tumor informed vs tumor naive (vs both?).

[Stephen V Liu, MD @StephenVLiu]

Dr. @charocampelo highlights some of the challenges with adjuvant targeted therapy and some unanswered questions regarding access and affordability, optimal duration, chronic toxicity considerations. Thoughtful discussion.

[Stephen V Liu, MD @StephenVLiu]

Dr. @JessicaJLinMD discusses adjuvant targeted therapy for resected NSCLC - how far are we comfortable extrapolating? Do we need phase III studies for all targets? Consider the cost of waiting.

[Stephen V Liu, MD @StephenVLiu]

Dr. @HendriksLizza debates the preference for perioperative over neoadjuvant for resectable NSCLC. Very pragmatic point over coverage and reimbursement - should regulatory authorities revisit this dogmatic approach?

[Stephen V Liu, MD @StephenVLiu]

Dr. @Alfdoc2 debates the value of adjuvant therapy following neoadjuvant for resectable NSCLC - is there a clear benefit that justifies the excess cost, particularly for those who achieve pCR?

[Stephen V Liu, MD @StephenVLiu]

Amazing group of thoughtful experts gathering in Porto for Lung Cancer Treatment Controversies to discuss some of the major uncertainties in lung cancer treatment. Very proud to coordinate this inaugural meeting with Drs. Antonio Araujo, @delvysra and @LuisPaz_Ares.

[Chul Kim @chulkimMD]

Honored to join @AMansfieldMD and Dr. Chris Nabel on a panel at The Thymic Carcinoma Center’s annual gala in Kansas City.

Thank you to the patients, caregivers, and advocates who shared their inspiring stories tonight. We have much more to do for people facing this rare cancer.

[Christian Rolfo @ChristianRolfo]

Clinical workshop at #ISLB26 discussing cases in a molecular tumor board.
@EddieSantosMD @JennaCanzoniero @StoverLab @drgandara
@jberchuck @KonVenetis #beatrizbellosillo
@isliquidbiopsy